Upsher-Smith Laboratories is recalling 73,844 bottles of Bumetanide Tablets (generic Bumex), a prescription diuretic medication, because testing found an unspecified degradation product that does not meet safety and quality standards. This recall affects 1 mg and 2 mg strengths in 100-count bottles sold nationwide, including Puerto Rico and Guam. Because the product is "out of specification," it may not maintain its intended potency or safety profile throughout its shelf life. Consumers who have these specific lots should contact their healthcare provider or pharmacist for guidance on continuing their treatment.
The tablets contain a degradation byproduct that exceeded acceptable purity limits, which could potentially impact the medication's effectiveness or lead to unexpected side effects. While no specific injuries have been reported, using a degraded medication means you may not be receiving the precise dose required to manage your condition.
Healthcare consultation and pharmacy return
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.